Detailed Information on Publication Record
2023
Relugolix kombinovaná terapie a symptomy děložní myomatózy - vybrané kazuistiky indikačního spektra a výsledků léčby
HUDEČEK, Robert, J. KLAT, K. POHL, A. PROKOPENKO, L. MIKULASEK et. al.Basic information
Original name
Relugolix kombinovaná terapie a symptomy děložní myomatózy - vybrané kazuistiky indikačního spektra a výsledků léčby
Name (in English)
Relugolix combination therapy and symptoms of uterine myomatosis – selected case reports of indication spectrum and treatment outcomes
Authors
HUDEČEK, Robert (203 Czech Republic, belonging to the institution), J. KLAT (203 Czech Republic), K. POHL (203 Czech Republic), A. PROKOPENKO (203 Czech Republic), L. MIKULASEK (203 Czech Republic), Soňa ŠIMOVÁ (703 Slovakia, belonging to the institution), P. KRCAL (203 Czech Republic), A. SEVCIK (203 Czech Republic) and P. TOMES (203 Czech Republic)
Edition
CESKA GYNEKOLOGIE-CZECH GYNAECOLOGY, PRAGUE, NAKLADATELSKE STREDISKO C L S J E PURKYNE, 2023, 1210-7832
Other information
Language
Czech
Type of outcome
Článek v odborném periodiku
Field of Study
30214 Obstetrics and gynaecology
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 0.400 in 2022
RIV identification code
RIV/00216224:14110/23:00133866
Organization unit
Faculty of Medicine
UT WoS
001173222000001
Keywords (in Czech)
relugolix kombinovaná terapie; symptomy děložních myomů
Keywords in English
relugolix combination therapy; uterine fibroid symptoms
Tags
Reviewed
Změněno: 21/3/2024 12:10, Mgr. Tereza Miškechová
V originále
Objective: An illustrative review of the indications for relugolix combination therapy (RCT) in the management of symptoms associated with uterine myomatosis. Methods: A set of annotated case reports from outpatient and clinical practice. Results: The file includes a non-invasive methodology for defining excessive menstrual bleeding using the pictorial bleeding assessment chart (PBAC). It also presents the use of RCT as a fertility-sparing procedure prior to elective myomectomy and the management of isthmic fi broids as an uterine factor of infertility. Cases of RCT of adenomyosis in primary sterility and in extragenital forms of endometriosis are commented. Emergent events associated with complications of myomatosis in pregnancy are represented by a case report of necrotizing diffuse myomatosis in puerperium. The differential-diagnostic confusion of adnexal pathology and myomatosis, RCT as a final solution to failed pharmacotherapy, and the alternative of hysterectomy in premenopause illustrate the diverse spectrum of indications for pharmacological treatment, including the possibility of dual therapy with RCT and aGnRH. Conclusion: Relugolix combination therapy as an effective and safe causal treatment expands the therapeutic spectrum and options for reproductive medicine specialists and registering gynaecologists. The availability of conservative treatment in combination with surgical treatment leads to optimalization and greater effectiveness of therapeutic procedures and increased quality of life for women with myomatosis.
In English
Objective: An illustrative review of the indications for relugolix combination therapy (RCT) in the management of symptoms associated with uterine myomatosis. Methods: A set of annotated case reports from outpatient and clinical practice. Results: The file includes a non-invasive methodology for defining excessive menstrual bleeding using the pictorial bleeding assessment chart (PBAC). It also presents the use of RCT as a fertility-sparing procedure prior to elective myomectomy and the management of isthmic fibroids as an uterine factor of infertility. Cases of RCT of adenomyosis in primary sterility and in extragenital forms of endometriosis are commented. Emergent events associated with complications of myomatosis in pregnancy are represented by a case report of necrotizing diff use myomatosis in puerperium. The differential-diagnostic confusion of adnexal pathology and myomatosis, RCT as a final solution to failed pharmacotherapy, and the alternative of hysterectomy in premenopause illustrate the diverse spectrum of indications for pharmacological treatment, including the possibility of dual therapy with RCT and aGnRH. Conclusion: Relugolix combination therapy as an effective and safe causal treatment expands the therapeutic spectrum and options for reproductive medicine specialists and registering gynaecologists. The availability of conservative treatment in combination with surgical treatment leads to optimalization and greater effectiveness of therapeutic procedures and increased quality of life for women with myomatosis.